# Inhibikase Therapeutics, Inc. (IKT) · Edgar & Edgarette company card

> Inhibikase Therapeutics (IKT) saw revenue fall 100% in FY2024 to $0 million, operating margin null against a -15.8% median for biological products, (no diagnostic substances), equity 96.2% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1750149 · fiscal year ended 2024-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/IKT) · [JSON](https://www.pops4.com/boards/company/IKT.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $0 |
| Revenue growth, 1 year | -100.0% |
| Revenue growth per year | — |
| Operating margin | -Infinity% (prior year -7712.0%) |
| Net margin | -Infinity% |
| Operating cash flow | −$19M |
| Capital spending | $0 |
| Free cash flow | −$19M |
| Cash | $98M |
| Long-term debt | — |
| Total assets | $99M |
| Total equity | $95M |
| Equity ÷ assets | 96.2% |
| Return on equity | -29.0% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 27.91 (safe zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Weathered boat · two warning signs · filed auditor change in the last 12 months; operating cash flow was negative (-$27.8M in FY2025)

## Edgarette's reading

Exposure: revenue $0K (FY2024). Experience: revenue down 100.0% on the year; operating margin null, down from -7712.0%. Soundness: equity 96.2% of assets, return on equity -29.0%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $0K and $0K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin null against a -15.8% median; growth -100.0% against 21.4%.

## Health Watch, last 12 months

- Item 4.01 Auditor change: 1, latest 2026-08-26 ([filing](https://www.sec.gov/Archives/edgar/data/1750149/000119312526368296/0001193125-26-368296-index.htm))
- Item 5.02 Director or officer change: 2, latest 2026-10-20 ([filing](https://www.sec.gov/Archives/edgar/data/1750149/000119312526426811/0001193125-26-426811-index.htm))

## Recent filings

- 8-K · filed 2026-10-20 · 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1750149/000119312526426811/0001193125-26-426811-index.htm)
- 8-K · filed 2026-09-08 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1750149/000119312526385293/0001193125-26-385293-index.htm)
- 8-K · filed 2026-08-26 · 4.01 Changes in Registrant's Certifying Accountant; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1750149/000119312526368296/0001193125-26-368296-index.htm)
- 10-Q · filed 2026-08-11 · [filing](https://www.sec.gov/Archives/edgar/data/1750149/000119312526344707/0001193125-26-344707-index.htm)
- 8-K · filed 2026-08-11 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1750149/000119312526344623/0001193125-26-344623-index.htm)
- 8-K · filed 2026-07-29 · 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1750149/000119312526323651/0001193125-26-323651-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001750149.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1750149

## Cite

POPS4, Edgar & Edgarette: Inhibikase Therapeutics, Inc. (IKT) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/IKT. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Its latest audited year is FY2025, which reports no revenue; the revenue figures and the range here are from FY2024, its last year with revenue on record. Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.